Article information
Full text is only aviable in PDF
BIBLIOGRAFIA
[1.]
E.H. Mlchler.
Seminars in Respiratory Medicine., 6 (1985), pp. 271
[2.]
M.A. Ajtken, S.B. Fiel.
Cystic Fibrosis, (1993),
[3.]
J.S. Elborn, D.J. Shale, J.R. Britton.
Cystic fibrosis·current survival and population estimates to the year 2000.
Thorax, 46 (1991), pp. 881-885
[4.]
M.R. Charfi, R. Matran, J. Regnard, A. Lockhart.
Mesure de Ia difference de potencial transepithelial nasal: un test diagnostique de Ia mucoviscidose.
Rev. Pneumologie Clin., 52 (1996), pp. 9-13
[6.]
S.A. Prasad.
Current concepts in physiotherapy.
Journal of the Royal Society of Medicine, 86 (1993), pp. 23-29
[7.]
Cystls Fibrosis Foundation Consensus Conference Defining the Criteria for a Cystic Fibrosls Diagnosis.
Clinical Practice Guidelines for Cystic Fibrosis; Cystic Fibrosis Fundation: Appendix I, (1997),
[8.]
Cystic Fibrosis Foundation.
Patient Registry, (1995),
[9.]
W. Burke, M.L. Ajtken.
The aging cystic fibrosis patient·presentations and problems.
Seminars in Respiratory and Critical Care Medicine, 15 (1994), pp. 383-390
[10.]
J.M. Polu, O. Lesur, N. Delorme.
La mucoviscidose de l’adulte.
Rev Prat, 40 (1990), pp. 1581-1586
[11.]
M. Daid, A.T. Hansen, P. Lange, B.G. Noerdesgaard.
Delta F508 heterozigosity in cystic fibrosis and susceptibility to asthma.
The Lancet, 351 (1998), pp. 1911-1913
[12.]
P.F. Pignatti, C. Bombieri, C. Marlgo, M. Benetaz Zo, M. Luisetti.
fucreased incidence ofcystic fibrosis gene mutations in adults with disseminated bronchiectasis.
Hum. Mol Genet, 4 (1995), pp. 635-639
[13.]
B.J. Wiatrak, C.M. Meyer, R.T. Cotton.
Cystic fibrosis presenting with sinus disease in children.
AJDC, 147 (1993), pp. 258-260
[14.]
M. Goossens, N. Ghanem, E. Girodon, B. Costes, P. Fanen.
La mucoviscidose: le gene CFTR, ses mutations. le conseiJ genetique.
Rev. Pneumol. Clin, 51 (1995), pp. I30-136
[15.]
R. Gervais, J.J. Lafitte, V. Dumur.
Sweat chloride and delta F508 mutation in chronic bronchitis or bronchiectasis.
Lancet, 342 (1993), pp. 997
[16.]
C. Colombo, A. Crosignani, M.G. Apostolo, M.T. Marzano, N. Bettinardi, A. Giunta.
Oral bile acids in CF-associated liver disease.
Journal of the Royal Society of Medicine, 87 (1994), pp. 20-24
[17.]
A.B. Atlas, S.R. Orenstein, O.M. Orenstein.
Pancreatitis in young children with cystic fibrosis.
J. Pediatr, 20 (1992), pp. 56-759
[18.]
L. Giovanbatttista, S. Pitzalis, R. Podda, M. Zanda, M. Silvetti, L. Caocci, et al.
A specific cystic fibrosis mutation (T338J) associated with the phenotype of isolated hypotonic dehydration.
J. Pediatr., 127 (1995), pp. 281-283
[19.]
I. Durieu, F. Bey Omar, J. Rollet, L. Calemard, D. Boggio, H. Lejeune, R. Gilly, Y. Morely, D.V. Durand.
Diagnostic criteria for cystic fibrosis in men with congenital absence of the vas deferente.
Medicine Baltimore, 74 (1995 Jan), pp. 42-47
[20.]
F.A. Abreu e Silva, J.A. Dodge, C. Barreto.
Orientações para o diagnóstico e acompanhamento da fibrose quistica,
[21.]
R.C. Stern.
The diagnosis of Cystic Fibrosis.
N Engl. J Med, 336 (1997), pp. 487-491
[22.]
X. Estivill.
Cystic Fibrosis mutations and clinical phenotypes,
[23.]
T.M. Murphy, C. Rudd, W. Samuelson.
Treatment of Cystic Fibrosis in Pulmonary and Critical Care Pharmacology and Therapeutics, pp. 882
[24.]
D. Hubert, F. Foucaud.
La Mucoviscidose·de l’enfant al’adulte.
Rev. Pneumol. Clin, 51 (1995), pp. 137-144
[25.]
T.F. Scanun.
Cystic fibrosis. Pulmonary Diseases and Disorders (AP Fishman), (1988), pp. 1275
[26.]
J.P. Baptista, M.A. Pêgo, M.Y. Martins, M.C. Loureiro.
Fibrose quiStica no adulto.
I, 3 (1997), pp. 39-47
[27.]
S.P. Conway, D.E. Stableforth, A.K. Webb.
The failing health care system for adult patients with cystic fibrosis.
Thorax, 53 (1998), pp. 3-4
[28.]
P.B. Davtsm, M. Drumm, M.W. Konstan.
Cystic fibrosis.
Am J Crit Care. Med, 154 (1996), pp. 1229-1256
[29.]
C. Ranasinha, B. Assoufi, S. Shak, et al.
Efficacy and safety of shon-tem1 administration of aerosolised rhDNAse in adults with stable stage cystic fibrosis.
Lancet., 342 (1993), pp. 199-202
[30.]
W.S. Chernick, G.J. Barbero.
Composition of tracheobronquial secretions in cystic fibrosis of the pancreas and bronchiectasis.
Pediatrics, 24 (1959), pp. 739-745
[31.]
S. Shak, D.J. Capon, R. Hellniss, et al.
RhDNAse reduces the viscosity of cystic fibrosis sputum.
Proc Natl. Acad. Sci. USA, 87 (1990), pp. 9188-9192
[32.]
H.J. Fuchs, D. Borowitz, D. Chrjtlansen, E. Morris, M. Nash, B. Ramsey, et al.
Effects of aerosolized rhDNAse on exacerbations of respiratory sintoms and on pulmonary function in patients with cystic fibrosis.
N. Engl J Med, 331 (1994), pp. 637-642
[33.]
M.E. Wohl.
Twelve-month improvement of pulmonary function in cystic fibrosis patients using aerosolized dornase alfa.
Dornase alfa in Clinical Series, 1 (1994), pp. 1-5
[34.]
G. Tournier, A. Sardet, C. Grosskopft, A. Bacu Lard, A. Delaisi.
Nouvelles aproches phannacologiques: Ia rhDNAse.
Rev Pneumol. Clin, 51 (1995), pp. 193-200
[35.]
A.E. O’Donnell, A.F. Barker, S. Ilowite, R.B. Fick.
Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNAse I.
Chest, 113 (1998), pp. 1329-1334
[36.]
B.A. Touleimat, C.S. Conoscenti, J.M. Fine.
Recombinant human DNAse in management of lobar atelectasis due to retained secretions.
Thorax, 50 (1995), pp. 1319-1321
[37.]
N. Hoiby.
Microbiology of Cystic Fibrosis.
Cystic Fibrosis,
[38.]
G. Lenoir.
Pseudomonas aerugmosa et mucoviscidose.
Rev Pneumol. Clin, 51 (1995), pp. 151-159
[39.]
B. Frederiksen, S. Lanng, C. Koch, N. Holby.
Improved survival in the danish center treated cystic fibrosis patients: results of aggresive treatment.
Pediatric Pulmonology, 21 (1996), pp. 153-158
[40.]
T.M. Murphy, C. Rudd, W. Samuelson.
Treatment of cystic fibrosis in Pulmonary and Critical Care Pharmacology and Therapeutics, pp. 893-899
[41.]
R.E. Kavanagh, J.D. Unadkat, A.L. Smith.
Drug disposition in cystic fibrosis.
Lung Biology Health and Disease, 4 (1993), pp. 91-136
[42.]
S. Mukhopadhyay, M. Singh, J.L. Cater, S. Ogston, M. Frankljn, R.E. Olver.
Nebulized antipseudomonal antibiotic therapy in cystic fibrosis·a meta-analysis of benefits and risks.
Thorax, 51 (1996), pp. 364-368
[43.]
J.R. Yakaskas, G.B. Mallory.
Lung transplantation in Cystic Fibrosis - Consensus Conference Statement.
Chest, 113 (1998), pp. 217-226
[44.]
Consensus Conference Pulmonary CompliCations of Cystic Fibrosis.
Clinical Practice Guidelines for Cystic Fibrosis; Cystic Fibrosis Fundation: Appendix rt, (1997),
[45.]
P. Scheid, D. Anthoine, M. Polu.
Traitment de Ia insuffisance respiratoire de Ia mucoviscidose.
Rev. Pneumol. Clin, 51 (1995), pp. 181-185
[46.]
Sub-Grupo De Ventiloterapia Domiciljaala Da Comissao De Trabalho De Reabilitacao Respiratorla.
Rev Port. Pneumol, 4 (1998), pp. 479-486
[47.]
J.R.W. Govan, J.W. Nelson.
Microbiology of cystic fibrosis lung infections: themes and issues.
Journal of the Royal Society of Medicine, 86 (1993), pp. 11-18
[48.]
Microbiology And Infectious Disease In Cystic Fibrosis.
Clinical Practice Guidelines for Cystic Fibrosis; Cystic Fibrosis Fundation: Appendix VIII, (1997),
[49.]
Editorial.
Pseudomonas cepacia- more than a hannless commensal?.
Lancet, 339 (1992), pp. 1385-1386
[50.]
M.J. Ledson, M.J. Gallagher, J.E. Corkill, C.A. Hart, M.J. Watshaw.
Cross infection between cystic fibrosis patients colonized with Burkhoderia cepacia.
Thorax, 53 (1998), pp. 432-436
[51.]
Y. Martins, J.P. Baptista, A. Pêgo, M.C. Loureiro, A.J.A. Robalo Cordeiro.
Fibrose quistica e tuberculose pulmonar-uma associacao rara: caso clinico.
Rev Port Pneumol, 2 (1996), pp. 347
[52.]
J.K. Torrens, P. Dawkins, S.P. Conway, E. Moya.
Non-tuberculosis mycobacteria in cystic fibrosis.
Thorax, 53 (1998), pp. 182-185
[53.]
J.C. Winck.
Micobacterias não tuberculosas e doença pulmonar.
Rev Port. Pneumol, II (1994), pp. 103-112
[54.]
S. Mrouch, A. Spock.
Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
Chest, 105 (1994), pp. 32-36
[55.]
I.A. Nelson, M.C. Callerame, R.H. Shwartz.
Aspergillosis and atopy in cystic fibrosis.
Am Rev. Respir Dis, 120 (1979), pp. 863-873
[56.]
A. Baculard, G. Tournier.
Aspergillose brochopulmonaire et mucoviscidose.
Rev. Pneumol. Clin, 51 (1995), pp. 160-163
[57.]
J.N. Allen, W.B. Davis.
Eosinophilic lung diseases.
Am. J. Respir. Crit. Care. Med, (1994), pp. 1423-1438
[58.]
S. Hemmann, W.H. Nikolalztk, M.H. Schoni, K. BlaSer, R. Cramerj.
Differential lgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergil10 sis or aspergillus allergy.
Eur. J. Immunol, 28 (1998), pp. 1155-1160
[59.]
P.L. Shah, S.F. Scott, M.E. Hodson.
Lobar atelectasis in cystic fibrosis and treatment with recombinant human DNAse I.
Respir. Med., 88 (1994), pp. 313-315
[60.]
B.L. Mark, C.M. Andersen.
Fibrocystis disease of the pancreas in a men aged 46.
Lancet, 1 (1960), pp. 365-367
[61.]
J.G. O’Shea.
Was Frederic Chopin’s ilness actually cystic fibrosis?.
The Medical Journal of Australia, 147 (1987), pp. 586-589
Copyright © 1999. Sociedade Portuguesa de Pneumologia/SPP
Open access
This work is licensed under a Creative Commons Attribution 4.0 International License.
Publish in
Pulmonology
Pulmonology
- Home
- All contents
- Publish your article
- About the journal
- Metrics
- Open access
Article options